Synthesis and Evaluation of Cytotoxic Activity of Certain Benzo[h]chromene Derivatives

Anticancer Agents Med Chem. 2021;21(8):963-986. doi: 10.2174/1871520620666200925103742.

Abstract

Background: Benzo[h]chromenes attracted great attention because of their widespread biological activities, including anti-proliferate activity, and the discovery of novel effective anti-cancer agents is imperative.

Objective: The main objective was to synthesize new benzo[h]chromene derivatives and some reported derivatives, and then test all of them for their anti-cancer activities.

Methods: The structures of the newly synthesized derivatives were confirmed by elemental and spectral analysis (IR, Mass, 1H-NMR and 13C-NMR). 35 compounds were selected by the National Cancer Institute (NCI) for single-dose testing against 60 cell lines and 3 active compounds were selected for 5-doses testing. Also, these 3 compounds were tested as EGFR-inhibitors; using sorafenib as standard, and as Tubulin polymerization inhibitors using colchicines as a standard drug. Moreover, molecular docking study for the most active derivative on these 2 enzymes was also carried out.

Results: Compounds 1a, 1c and 2b have the highest activities among all 35 tested compounds especially compound 1c.

Conclusion: compound 1c has promising anti-cancer activities compared to the used standards and may need further modification and investigations.

Keywords: 5-doses testing; Benzo[h]chromene; EGFR-inhibitors; anti-cancer activity; synthesis; tubulin polymerization inhibitors.

MeSH terms

  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / pharmacology
  • Benzopyrans / chemical synthesis*
  • Benzopyrans / pharmacology
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Colchicine / analogs & derivatives
  • Colchicine / pharmacology
  • Colchicine / standards
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / antagonists & inhibitors
  • Humans
  • Molecular Docking Simulation
  • Molecular Structure
  • Protein Kinase Inhibitors / chemical synthesis*
  • Protein Kinase Inhibitors / pharmacology
  • Sorafenib / pharmacology
  • Sorafenib / standards
  • Structure-Activity Relationship
  • Tubulin Modulators / chemical synthesis*
  • Tubulin Modulators / pharmacology

Substances

  • Antineoplastic Agents
  • Benzopyrans
  • Protein Kinase Inhibitors
  • Tubulin Modulators
  • colchicone
  • Sorafenib
  • ErbB Receptors
  • Colchicine